Fesoterodine Fumarate NDC 62332-175

NDC codes

FDA NDC Directory

Product NDC (as listed)62332-175Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62332-0175Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
62332-175-10	62332017510	100 TABLET, EXTENDED RELEASE in 1 CARTON (62332-175-10)Marketed from Jan 6, 2023
62332-175-30	62332017530	30 TABLET, EXTENDED RELEASE in 1 BOTTLE (62332-175-30)Marketed from Jan 6, 2023
62332-175-90	62332017590	90 TABLET, EXTENDED RELEASE in 1 BOTTLE (62332-175-90)Marketed from Jan 6, 2023
62332-175-91	62332017591	1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (62332-175-91)Marketed from Jan 6, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fesoterodine Fumarate
Generic name (nonproprietary): fesoterodine fumarate
Active ingredients: Fesoterodine fumarate — 4 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Alembic Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 204973
Marketing start: Jan 6, 2023
Listing expires: Dec 31, 2026
Identifiers: Product ID 62332-175_2fc9ba3f-2336-45b8-9020-bffc1298a6e0SPL ID 2fc9ba3f-2336-45b8-9020-bffc1298a6e0SPL set ID 299db62d-9658-4796-b449-657fa859c5cdRxCUI 810071, 810077UNII EOS72165S7UPC 0362332176304, 0362332175307

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462332017510 followed by a unit qualifier and the quantity

Package 62332-0175-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 17, 2025.

Indications (excerpt from the label)

Fesoterodine fumarate extended-release tablets are indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2 ) 1.1 Adult Overactive Bladder Fesoterodine fumarate extended-release tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity Fesoterodine fumarate extended-release tablets are indicated for the treatment of neurogenic detrusor overactivity…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 204973

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 204973
Product	Strength	Form · route	Labeler	Product NDC
Fesoterodine Fumarate	Fesoterodine fumarate 4 mg/1	Tablet, Extended releaseOral	Alembic Pharmaceuticals Limited	46708-175
Fesoterodine Fumarate	Fesoterodine fumarate 8 mg/1	Tablet, Extended releaseOral	Alembic Pharmaceuticals Limited	46708-176
Fesoterodine Fumarate	Fesoterodine fumarate 8 mg/1	Tablet, Extended releaseOral	Alembic Pharmaceuticals Inc.	62332-176